Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01772602 · ClinicalTrials.gov registry record

The National Amyotrophic Lateral Sclerosis Registry

A clinical trial of Amyotrophic Lateral Sclerosis, sponsored by Centers for Disease Control and Prevention.

Recruiting
Registry status
30,000
Enrollment target
1
Study location

NCT01772602 is a study of Amyotrophic Lateral Sclerosis that is actively recruiting participants, run by Centers for Disease Control and Prevention. The registered enrollment target is 30,000 participants, above the 604-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (4867% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01772602, a study of Amyotrophic Lateral Sclerosis, is actively recruiting participants, sponsored by Centers for Disease Control and Prevention.

RECRUITING
Registry status
30,000 participants
Enrollment target
1
Study location

Study Summary

The purpose of this registry is to (A) better describe the incidence and prevalence of Amyotrophic Lateral Sclerosis (ALS) in the United States;(B) examine appropriate factors, such as environmental and occupational, that may be associated with the disease; (C) better outline key demographic factors (such as age, race or ethnicity, gender, and family history of individuals who are diagnosed with the disease) associated with the disease; and (D) better examine the connection between ALS and other motor neuron disorders that can be confused with ALS, misdiagnosed as ALS, and in some cases progress to ALS.

Study Locations (1)

Georgia

  • CDC - Atlanta

Trial Details

FieldValue
Enrollment Target 30,000 participants
Start Date 2010-10
Est. Completion 2040-12

What the Registry Record Tells You About NCT01772602

The ClinicalTrials.gov registry entry for NCT01772602 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 30,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 604-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (4867% higher). The listed sponsor is Centers for Disease Control and Prevention, which has 139 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Amyotrophic Lateral Sclerosis appearing as the primary indexed condition, and to 0 interventions.

NCT01772602 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.

Frequently Asked Questions

What is clinical trial NCT01772602 about?

NCT01772602 is a clinical study titled "The National Amyotrophic Lateral Sclerosis Registry". The purpose of this registry is to (A) better describe the incidence and prevalence of Amyotrophic Lateral Sclerosis (ALS) in the United States;(B) examine appropriate factors, such as environmental and occupational, that may be associated with the disease; (C) better outline key demographic factors...

What is the current status of trial NCT01772602?

This trial is currently recruiting. The enrollment target is 30,000 participants. The study started on 2010-10. Estimated completion is 2040-12.

What conditions does trial NCT01772602 study?

This clinical trial studies the following conditions: Amyotrophic Lateral Sclerosis.

Who is sponsoring clinical trial NCT01772602?

This trial is sponsored by Centers for Disease Control and Prevention, which has 139 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01772602 being conducted?

This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Amyotrophic Lateral Sclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.